Merck ADC lung cancer treatment shows nearly 50% tumor shrinkage in mid-stage trial, heading to FDA.
• Merck and Daiichi Sankyo report 50% tumor shrinkage in trial.
• Mid-stage trial focuses on small cell lung cancer treatment.
• ADC heading to FDA for potential approval.
Merck and Daiichi Sankyo report that nearly half of patients with small cell lung cancer experienced significant tumor shrinkage. This result comes from a mid-stage trial of their antibody-drug conjugate (ADC). The companies are now preparing to submit the data to the FDA for potential approval. Read more about the trial results.
Why it matters
The ADC developed by Merck and Daiichi Sankyo targets an aggressive form of lung cancer. Small cell lung cancer is known for its rapid progression and limited treatment options. Therefore, the nearly 50% tumor shrinkage observed in the trial is significant. This could potentially offer a new therapeutic option for patients who have limited alternatives.
What’s next
The companies plan to submit their findings to the FDA, aiming for regulatory approval. If approved, this ADC could become a new standard of care for small cell lung cancer. Meanwhile, further studies may be conducted to confirm these findings and explore additional indications. For more insights on clinical trials and R&D, visit our Clinical Trials & R&D section.